SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Aurobindo Pharma - Quaterly Results

27 May 2023 Evaluate
The revenue zoomed 22.87% to Rs. 35474.40 millions for the quarter ended March 2023 as compared to Rs. 28871.70 millions during the corresponding quarter last year.The Net proft of the company remain more or less same to Rs. 6448.00  millions from Rs. 8021.60 millions ,decline by -19.62%.OP of the company witnessed a marginal growth to 9800.00 millions from 9203.40 millions in the same quarter last year.


(Rs. in Million)


  Quarter ended Year to Date Year ended
  202303 202203 % Var 202303 202203 % Var 202303 202203 % Var
Sales 35474.40 28871.70 22.87 127922.80 112871.40 13.33 127922.80 112871.40 13.33
Other Income 2881.70 4133.70 -30.29 4337.60 6709.90 -35.36 4337.60 6709.90 -35.36
PBIDT 9800.00 9203.40 6.48 21646.80 21443.90 0.95 21646.80 21443.90 0.95
Interest 489.70 49.10 897.35 1149.80 169.40 578.75 1149.80 169.40 578.75
PBDT 9310.30 8407.20 10.74 20497.00 20527.40 -0.15 20497.00 20527.40 -0.15
Depreciation 1150.00 1012.20 13.61 4353.50 4152.60 4.84 4353.50 4152.60 4.84
PBT 8160.30 7395.00 10.35 16143.50 16374.80 -1.41 16143.50 16374.80 -1.41
TAX 1712.30 -626.60 -373.27 3839.40 1827.70 110.07 3839.40 1827.70 110.07
Deferred Tax -26.10 -880.70 -97.04 -230.80 -1969.30 -88.28 -230.80 -1969.30 -88.28
PAT 6448.00 8021.60 -19.62 12304.10 14547.10 -15.42 12304.10 14547.10 -15.42
Equity 585.90 585.90 0.00 585.90 585.90 0.00 585.90 585.90 0.00
PBIDTM(%) 27.63 31.88 -13.34 16.92 19.00 -10.93 16.92 19.00 -10.93

Aurobindo Pharma Share Price

1385.65 -0.45 (-0.03%)
17-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1675.20
Dr. Reddys Lab 1235.40
Cipla 1238.30
Zydus Lifesciences 942.55
Lupin 2324.25
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×